Mild Cognitive Impairment clinical trials

Explore recruiting mild cognitive impairment clinical trials.

Recruiting mild cognitive impairment studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mild Cognitive Impairment trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Placebo-Controlled, Double-Blind, Parallel-Group, 18 Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

Sweden, Spain, Italy, Germany, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE 1B DOSE RANGE FINDING STUDY OF PHENSERINE COMPARED TO DONEPEZIL IN PARTICIPANTS WITH EARLY OR MILD ALZHEIMER’S DISEASE

Norway

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Effects of NTRX-07 in Subjects with Mild Cognitive Impairment (MCI) or Mild to Moderate Alzheimer’s Disease (AD) (SPPN-AD)

Poland, Hungary, Czechia

Therapeutic exploratory (Phase II) EU CTIS Study details

Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease.

France

Therapeutic use (Phase IV) EU CTIS Study details

Mild Cognitive Impairment trials by city

Mild Cognitive Impairment in Toronto Mild Cognitive Impairment in Vancouver Mild Cognitive Impairment in Montreal Mild Cognitive Impairment in Calgary Mild Cognitive Impairment in Edmonton Mild Cognitive Impairment in Ottawa Mild Cognitive Impairment in Winnipeg Mild Cognitive Impairment in Quebec City Mild Cognitive Impairment in Hamilton Mild Cognitive Impairment in Kitchener Mild Cognitive Impairment in London Mild Cognitive Impairment in Halifax Mild Cognitive Impairment in New York Mild Cognitive Impairment in Los Angeles Mild Cognitive Impairment in Chicago Mild Cognitive Impairment in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease